Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4-NF-κB signaling

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 295-300

  Babazada, Hasan ^a   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Arthritis; Heparin nanoparticles; Inflammation; NF B; Toll like receptor 4

Indexed keywords

ARTHRITIS; INFLAMMATION; SELF-ASSEMBLING; TOLL-LIKE RECEPTOR 4;

GLYCOL; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NANOPARTICLE; SPHINGOSINE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; COLLAGEN TYPE 2; CYTOKINE; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG POTENCY; EXPERIMENTAL ARTHRITIS; FOOT PAD; HISTOPATHOLOGY; INFLAMMATORY CELL; JOINT DESTRUCTION; MACROPHAGE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SWELLING; SYNOVIAL FLUID; ANALOGS AND DERIVATIVES; ANIMAL; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHEMISTRY; DBA MOUSE; DRUG EFFECTS; JOINT; MALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; CYTOKINES; DENDRITIC CELLS; GLYCOLS; HEPARIN; IMMUNOGLOBULINS; JOINTS; MACROPHAGES; MALE; MICE; MICE, INBRED DBA; NANOPARTICLES; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84907699489     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.015     Document Type: Article

References (44)

1. U. Müller-Ladner, T. Pap, and R.E. Gay Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis Nat. Rev. Rheumatol. 1 2005 102 110
2. M.F. Roelofs, L.A. Joosten, and S. Abdollahi-Roodsaz The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells Arthritis Rheum. 52 2005 2313 2322
3. Q.Q. Huang, and R.M. Pope The role of toll-like receptors in rheumatoid arthritis Curr. Rheumatol. Rep. 11 2009 357 364
4. G.S. Firestein Evolving concepts of rheumatoid arthritis Nature 423 2003 356 361
5. A.N. Theofilopoulos, R. Gonzalez-Quintial, and B.R. Lawson Sensors of the innate immune system: their link to rheumatic diseases Nat. Rev. Rheumatol. 6 2010 146 156
6. F.G. Goh, and K.S. Midwood Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis Rheumatology (Oxford) 51 2012 7 23
7. A. Marshak-Rothstein, and I.R. Rifkin Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease Annu. Rev. Immunol. 25 2007 419 441
8. T.R. Radstake Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma Arthritis Rheum. 50 2004 3856 3865
9. C. Ospelt Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis Arthritis Rheum. 58 2008 3684 3692
10. J.Y. Choe, B. Crain, and S.R. Wu Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling J. Exp. Med. 197 2003 537 542
11. E.K. Lee, S.M. Kang, and D.J. Paik Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS Int. Immunol. 17 2005 325 333
12. M. Pierer, U. Wagner, and M. Rossol Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice PLoS ONE 6 2011 e23539
13. K. Midwood, S. Sacre, and A.M. Piccinini Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease Nat. Med. 15 2009 774 780
14. J.S. Park, D. Svetkauskaite, and Q. He Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein J. Biol. Chem. 279 2004 7370 7377
15. M.F. Roelofs, W.C. Boelens, and L.A. Joosten Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis J. Immunol. 176 2006 7021 7027
16. J. Sokolove, X. Zhao, and P.E. Chandra Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor Arthritis Rheum. 63 2011 53 62
17. Y. Tamaki, Y. Takakubo, and T. Hirayama Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis J. Rheumatol. 38 2011 810 820
18. J.M. Reynolds, G.J. Martinez, and Y. Chung Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation Proc. Natl. Acad. Sci. U. S. A. 109 2012 13064 13069
19. J.S. Smolen, and G. Steiner Therapeutic strategies for rheumatoid arthritis Nat. Rev. Drug Discov. 2 2003 473 488
20. H. Babazada, F. Yamashita, S. Yanamoto, and M. Hashida Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4-NF-kB signaling J. Control. Release 2014 10.1016/j.jconrel.2014.09.011
21. E. Young The anti-inflammatory effects of heparin and related compounds Thromb. Res. 122 6 2008 743 752
22. D.J. Tyrrell, A.P. Horne, K.R. Holme, J.M. Preuss, and C.P. Page Heparin in inflammation: potential therapeutic applications beyond anticoagulation Adv. Pharmacol. 46 1999 151 208
23. H.E. Conrad, and Y. Guo Structural analysis of periodate-oxidized heparin Adv. Exp. Med. Biol. 313 1992 31 36
24. W. Yeeprae, S. Kawakami, and F. Yamashita Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages J. Control. Release 114 2006 193 201
25. P.L. Podolin, J.F. Callahan, and B.J. Bolognese Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB kinase 2, TPCA-1(2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation J. Pharmacol. Exp. Ther. 312 2005 373 381
26. H. Hata, N. Sakaguchi, and H. Yoshitomi Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice J. Clin. Invest. 114 2004 582 588
27. Q. Li, and I.M. Verma NF-kappaB regulation in the immune system Nat. Rev. Immunol. 2 2002 725 734
28. S.S. Makarov NF-kappa B, in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction Arthritis Res. 3 2001 200 206
29. H. Asahara, M. Asanuma, and N. Ogawa High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis Biochem. Mol. Biol. Int. 37 1995 827 832
30. S. Agrawal, R. Misra, and A. Aggarwal Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA Clin. Rheumatol. 26 2007 201 204
31. S. Bas, T.V. Perneger, and E. Mikhnevitch Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis Rheumatology (Oxford) 39 2000 1082 1088
32. G.J. Silverman, J. Vas, and C. Grönwall Protective autoantibodies in the rheumatic diseases: lessons for therapy Nat. Rev. Rheumatol. 9 2013 291 300
33. W.H. Robinson, T.M. Lindstrom, and R.K. Cheung Mechanistic biomarkers for clinical decision making in rheumatic diseases Nat. Rev. Rheumatol. 9 2013 267 276
34. M.W. Boulé, C. Broughton, and F. Mackay Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes J. Exp. Med. 199 2004 1631 1640
35. L.G. Francisco, M.V.A. Jose, G. Francisco, L. Rafael, M.V.J. Francisco, and C.G.F. Juan Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes J. Pharm. Pharmacol. 45 1993 576 578
36. W.C. Foong, and K.L. Green The retention and distribution of dual-labeled liposomes injected into arthritic joints Br. J. Pharmacol. 80 1983 522
37. N.C. Phillips, P. Page-Thomas, C.G. Knight, and J.T. Dingle Liposome-incorporated corticosteroids. II. Therapeutic activity in experimental arthritis Ann. Rheum. Dis. 38 1979 553 557
38. D.J. Burgess, and S.S. Davis Potential use of albumin microspheres as a drug delivery system. II. In vivo deposition and release of steroids Int. J. Pharm. 46 1988 69 76
39. K.E. Brown, K. Leong, C.-H. Huang, R. Dalal, G.D. Green, H.B. Haimes, P.A. Jimenez, and J. Bathon Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint Arthritis Rheum. 41 1998 2185 2195
40. M.J. D'Souza, and P. DeSouza Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats Drug Dev. Ind. Pharm. 24 1998 841 852
41. M. Tuncay, S. Calis, H.S. Kas, M.T. Ercan, I. Peksoy, and A.A. Hincal Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation Int. J. Pharm. 195 2000 179 188
42. C.H. Evans, V.B. Kraus, and L.A. Setton Progress in intra-articular therapy Nat. Rev. Rheumatol. 10 1 2014 11 22
43. N. Butoescu, O. Jordan, and E. Doelker Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance Eur. J. Pharm. Biopharm. 73 2 2009 205 218
44. D.A. Rothenfluh, H. Bermudez, C.P. O'neil, and J.A. Hubbell Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage Nat. Mater. 7 2008 248 254